|

BAFF CAR-T Clinical Trials

2 actively recruiting trials across 1 location

Also known as: LMY-920

Pipeline

Phase 1: 2

Top Sponsors

  • Paolo Caimi, MD1
  • Luminary Therapeutics1

Indications

  • Cancer2
  • Refractory CLL1
  • Relapsed CLL1
  • Refractory Lymphoma1
  • Lymphoma, Non-Hodgkin Lymphoma, B-Cell1

Cleveland, Ohio2 trials

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma

University Hospitals Seidman Cancer Center

Phase 1
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.